Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04746209 · ClinicalTrials.gov registry record · Phase 2
Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT
A Phase 2 study of B-cell Acute Lymphoblastic Leukemia and B-cell Childhood Acute Lymphoblastic Leukemia, sponsored by Medical College of Wisconsin.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT04746209: Recruiting Phase 2 study of B-cell Acute Lymphoblastic Leukemia and B-cell Childhood Acute Lymphoblastic Leukemia, sponsored by Medical College of Wisconsin.
NCT04746209 is a Phase 2 study of B-cell Acute Lymphoblastic Leukemia and B-cell Childhood Acute Lymphoblastic Leukemia that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 25 participants, below the 88-participant average among 21 other B-cell Acute Lymphoblastic Leukemia trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04746209, a Phase 2 study of B-cell Acute Lymphoblastic Leukemia and B-cell Childhood Acute Lymphoblastic Leukemia, is actively recruiting participants, sponsored by Medical College of Wisconsin.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial will assess the feasibility of alpha/beta T-cell and B-cell depleted allogeneic hematopoietic cell transplantation (HCT) followed by blinatumomab therapy for high-risk B cell acute lymphoblastic leukemia (ALL) as a means of reducing rates of subsequent relapse and improving survival, while also minimizing treatment-related morbidity/ mortality and late effects. The conditioning regimens will be dependent on the patient's minimal residual disease (MRD) status prior to HCT using high throughput sequencing.
Primary Outcome
Percentage of patients who are able to receive the blinatumomab infusion at day +100 post-HCT and complete a minimum of 14/28 planned days
Conditions Studied
Interventions
- DRUG Blinatumomab
- DEVICE Alpha/Beta T-cell and B-cell depleted HCT
Study Locations (1)
Wisconsin
- Children's Hospital of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 2 |
What NCT04746209 shows while recruiting
NCT04746209 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 88-participant average among 21 other B-cell Acute Lymphoblastic Leukemia trials with a reported enrollment target (72% lower).
The record links to 3 conditions, with B-cell Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Blinatumomab is the first listed.
NCT04746209 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04746209 about?
NCT04746209 is a clinical study titled "Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT". This trial will assess the feasibility of alpha/beta T-cell and B-cell depleted allogeneic hematopoietic cell transplantation (HCT) followed by blinatumomab therapy for high-risk B cell acute lymphoblastic leukemia (ALL) as a means of reducing rates of subsequent relapse and improving survival, whil...
What is the current status of trial NCT04746209?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2021-02-01. Estimated completion is 2029-12-31.
What conditions does trial NCT04746209 study?
This clinical trial studies the following conditions: B-cell Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, B-Cell ALL, Childhood.
What interventions are being tested in trial NCT04746209?
The interventions under investigation include: Blinatumomab (DRUG), Alpha/Beta T-cell and B-cell depleted HCT (DEVICE).
Who is sponsoring clinical trial NCT04746209?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04746209 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-cell Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04746209's enrollment target sits among peer trials
25 21st of 21 higher than 1 of 21 other B-cell Acute Lymphoblastic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other B-cell Acute Lymphoblastic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
RECRUITING · Phase 2
-
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
RECRUITING · Phase 2
-
A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
RECRUITING · Phase 2
-
A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)
ACTIVE NOT RECRUITING · Phase 2
-
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
ACTIVE NOT RECRUITING · Phase 2
-
Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI